1851 related articles for article (PubMed ID: 16988532)
41. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
42. [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Qian SX; Li JY; Wu HX; Zhang R; Hong M; Xu W; Qiu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):464-7. PubMed ID: 19379589
[TBL] [Abstract][Full Text] [Related]
43. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
[TBL] [Abstract][Full Text] [Related]
44. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
[TBL] [Abstract][Full Text] [Related]
45. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
Chen YC; Lin SF; Yao M; Chen TY; Tsao CJ; Chen TP
Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
[TBL] [Abstract][Full Text] [Related]
46. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
[TBL] [Abstract][Full Text] [Related]
47. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
48. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
49. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
Damon LE; Johnston LJ; Ries CA; Rugo HS; Case D; Ault K; Linker CA
Cancer Chemother Pharmacol; 2004 Jun; 53(6):468-74. PubMed ID: 15138711
[TBL] [Abstract][Full Text] [Related]
50. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
51. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
52. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM; Estey E; Beran M
Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
[TBL] [Abstract][Full Text] [Related]
53. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
de la Rubia J; Sanz GF; Martín G; Sempere A; Picón I; Carral A; Larrea L; Martínez J; Soler MA; Bonanad S; López F; Jarque I; Sanz MA
Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390
[TBL] [Abstract][Full Text] [Related]
54. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
[TBL] [Abstract][Full Text] [Related]
55. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
[TBL] [Abstract][Full Text] [Related]
56. [Efficacy of IA regimen followed by FLAG regimen in the treatment of acute myeloid leukaemia].
Qian SX; Li JY; Hong M; Lu H; Wu HX; Qiu HX; Zhang SJ; Chen LJ; Xu W; Sheng RL
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):22-5. PubMed ID: 19563030
[TBL] [Abstract][Full Text] [Related]
57. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
Tafuri A; De Felice L; Petrucci MT; Mascolo MG; Ricciardi MR; Ciliberti C; Martelli MP; Petti MC
Cytokines Mol Ther; 1995 Dec; 1(4):301-7. PubMed ID: 9384683
[TBL] [Abstract][Full Text] [Related]
58. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
[TBL] [Abstract][Full Text] [Related]
59. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
60. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
